Common TitleStudy 114
Official Title A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Cobicistat (GS-9350)-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Phase Phase III
ClinicalTrials.gov NCT01108510
Treatments
Atazanavir
, Atazanavir
Tradename:ReyatazOther Names:ATVClass:Protease Inhibitors (PI)Atazanavir-Cobicistat
, Atazanavir-Cobicistat
Tradename:EvotazOther Names:ATV-COBIClass:Protease Inhibitors (PI)Cobicistat
Cobicistat
Tradename:TybostOther Names:COBIClass:Pharmacokinetic EnhancersCategories Treatment-Naive
Funding
IndustryGilead Sciences
References
- Gallant JE, Koenig E, Andrade-Villanueva J, et al. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. J Infect Dis. 2013;208:32-9.
- Gallant JE, Koenig E, Andrade-Villanueva JF, et al. Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results. J Acquir Immune Defic Syndr. 2015;69:338-40.